Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $146.00 at Leerink Partners

Gilead Sciences (NASDAQ:GILD) had its target price dropped by stock analysts at Leerink Partners from $148.00 to $146.00 in a research report issued on Friday,MarketScreener reports. Leerink Partners’ target price suggests a potential upside of 11.17% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on GILD. Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Needham & Company LLC reiterated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a report on Monday, February 23rd. Citigroup lifted their price objective on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Finally, Argus lifted their price target on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $157.15.

Gilead Sciences Price Performance

GILD opened at $131.33 on Friday. The stock has a fifty day simple moving average of $139.59 and a two-hundred day simple moving average of $132.87. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The company has a market cap of $163.01 billion, a price-to-earnings ratio of 17.89, a price-to-earnings-growth ratio of 1.77 and a beta of 0.31. Gilead Sciences has a 12-month low of $96.18 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 49.45%. The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts predict that Gilead Sciences will post 8.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the insider directly owned 128,779 shares in the company, valued at $18,152,687.84. The trade was a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 63,000 shares of company stock valued at $9,238,250. Company insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors have recently added to or reduced their stakes in GILD. Brighton Jones LLC increased its stake in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $215,000. Sivia Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 602 shares in the last quarter. Ieq Capital LLC grew its position in shares of Gilead Sciences by 12.0% in the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC grew its position in shares of Gilead Sciences by 18.6% in the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 674 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Truist Financial reaffirmed its buy rating on Gilead and raised its price target to $157 from $155, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Gilead reported Q1 EPS of $2.03 and revenue of $6.96 billion, both ahead of analyst expectations, supported by HIV and Trodelvy sales growth. Yahoo Finance
• Positive Sentiment: The company raised its Yeztugo 2026 sales guidance to $1 billion from $800 million, signaling stronger-than-expected launch momentum. Yahoo Finance
• Neutral Sentiment: RBC slightly reduced its price target to $122 from $123 and kept a sector perform view, suggesting a more cautious stance but no major change in thesis. Benzinga
• Negative Sentiment: Gilead cut its 2026 EPS guidance to a loss range of -$1.05 to -$0.65, a major deterioration from prior profit expectations, due to acquisition charges and financing costs. Reuters
• Negative Sentiment: Investors also appear concerned that near-term growth is being driven more by older products like Descovy and Biktarvy than by the much-anticipated Yeztugo launch, creating questions about the pace of future growth. Yahoo Finance

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.